Gabapentin (Neurontin)

Gabapentin, marketed under the brand name Neurontin for human use, is an anticonvulsant medication that has gained significant recognition in equine medicine for its anxiolytic and analgesic properties. Originally developed to treat seizures and neuropathic pain in humans, gabapentin has become an increasingly valuable tool in veterinary practice for managing anxiety-related behaviors and chronic pain conditions in horses. The medication belongs to the gabapentinoid class of drugs and represents an important advancement in equine behavioral medicine, offering practitioners an additional option for horses that do not respond adequately to traditional sedatives or require long-term anxiety management without the significant sedation associated with other medications.

The mechanism of action of gabapentin involves modulation of voltage-gated calcium channels in the central nervous system. By binding to the alpha-2-delta subunit of these calcium channels, gabapentin reduces the release of excitatory neurotransmitters, effectively dampening neural hyperexcitability. This unique mechanism differentiates gabapentin from traditional sedatives and anxiolytics, as it does not work through GABA receptors despite its name suggesting otherwise. The modulation of calcium channel activity results in decreased anxiety responses and reduced pain signaling, making it particularly effective for conditions involving both behavioral and sensory components such as headshaking syndrome.

Gabapentin is available exclusively in oral formulations for equine use, including capsules, tablets, and oral solutions. The medication is typically administered once or twice daily depending on the condition being treated and the individual horse's response. Administration is relatively straightforward, as the medication can be given directly by mouth or mixed with a small amount of feed. The oral solution formulation offers flexibility in dosing, particularly for horses requiring precise dose adjustments. Palatability is generally acceptable, though some horses may initially resist the medication, requiring creative administration strategies such as mixing with molasses or applesauce.

The safety profile of gabapentin in horses is generally favorable when used appropriately under veterinary supervision. However, because gabapentin is used off-label in equine patients, careful attention to dosing and monitoring is essential. The medication undergoes minimal hepatic metabolism and is primarily excreted unchanged through the kidneys, which has implications for horses with renal compromise. Veterinary guidance is crucial for determining appropriate dosing based on the individual horse's weight, condition being treated, and concurrent medications. Abrupt discontinuation should be avoided after extended use, as gradual tapering is recommended to prevent potential rebound effects.

The primary indication for gabapentin in equine medicine is the management of anxiety and anxiety-related behavioral disorders. Horses experiencing situational anxiety, generalized anxiety, or specific phobias may benefit significantly from gabapentin therapy. The medication is particularly valuable for horses that exhibit excessive nervousness, reactivity, or stress responses that interfere with training, handling, or quality of life. Unlike traditional sedatives that produce marked sedation, gabapentin typically reduces anxiety while allowing the horse to remain alert and functional, making it suitable for horses that need to maintain performance capabilities or learn new behaviors during treatment.

Beyond anxiety management, gabapentin has emerged as an important treatment option for equine headshaking syndrome, a frustrating and often debilitating condition characterized by involuntary vertical head movements. Headshaking syndrome is believed to involve trigeminal nerve sensitization, and gabapentin's ability to modulate neural excitability makes it a logical therapeutic choice. Many horses with headshaking syndrome show meaningful improvement with gabapentin therapy, particularly when the condition has a neuropathic component. The medication may be used as monotherapy or in combination with other treatments depending on the severity and underlying cause of the headshaking behavior.

Gabapentin is also utilized for neuropathic pain management in horses, addressing chronic pain conditions that do not respond adequately to traditional non-steroidal anti-inflammatory drugs. Conditions such as nerve injuries, post-surgical pain with a neuropathic component, and chronic laminitis-associated pain may benefit from gabapentin's analgesic properties. The medication works differently than NSAIDs, targeting the central processing of pain signals rather than peripheral inflammation, which makes it a valuable adjunct therapy for complex pain presentations. Veterinarians may recommend gabapentin for horses experiencing allodynia or hyperalgesia, where normal stimuli produce exaggerated pain responses.

Additional clinical applications include pre-procedural anxiety management, where gabapentin may be administered before veterinary examinations, farrier visits, or other potentially stressful procedures. Some practitioners use gabapentin as part of multimodal protocols for horses with severe anxiety during trailering, clipping, or veterinary procedures. The medication has also been explored for managing stereotypic behaviors such as cribbing and weaving, though evidence for these applications remains limited. Performance horses dealing with competition anxiety or stress-related issues may be candidates for gabapentin therapy, though competition regulations must be carefully considered.

When selecting gabapentin for equine patients, veterinarians consider several factors including the nature and severity of the anxiety or pain condition, the horse's response to previous treatments, and the need for ongoing functional capacity. Gabapentin is often chosen when traditional sedatives produce excessive sedation, when long-term management is anticipated, or when the condition involves a clear neuropathic component. The relatively favorable side effect profile and lack of controlled substance restrictions make gabapentin an attractive option for many situations. Cost considerations are generally reasonable, as generic gabapentin is widely available, though the need for relatively high doses in horses compared to smaller species does impact overall treatment costs.

Dosing protocols for gabapentin in horses require careful veterinary determination, as the medication is used off-label and optimal equine dosing continues to be refined through clinical experience and research. The veterinarian will establish the appropriate dose based on the individual horse's body weight, the condition being treated, concurrent medications, and response to therapy. Accurate weight determination is critical, as horses vary tremendously in size from miniatures weighing around 200 pounds to draft breeds exceeding 2,000 pounds. Weight tapes provide reasonable estimates, but scale weights are preferable when available, particularly for horses at the extremes of the size spectrum or those requiring precise dosing.

Typical dosing ranges for gabapentin in horses generally fall between 2.5 to 20 mg/kg administered orally, with frequency ranging from once daily to three times daily depending on the clinical situation. For anxiety management, lower doses administered once or twice daily may be sufficient, while neuropathic pain conditions often require higher doses given more frequently. Some protocols begin with a lower dose that is gradually increased until the desired effect is achieved, allowing for identification of the minimum effective dose for each individual horse. Maximum daily doses vary by indication and should be determined by the prescribing veterinarian based on clinical response and tolerance.

Treatment duration with gabapentin varies considerably based on the underlying condition. For situational anxiety related to specific events, short-term treatment surrounding the triggering event may be appropriate. Chronic conditions such as headshaking syndrome or neuropathic pain typically require ongoing therapy, potentially for months or even long-term. The veterinarian will establish appropriate follow-up intervals to assess therapeutic response and adjust dosing as needed. Some horses may require dose adjustments over time as their condition evolves or as tolerance develops. Regular reassessment helps ensure the treatment plan remains optimized for the individual patient.

Administration of gabapentin to horses is accomplished orally, with several practical approaches available depending on the formulation and individual horse's preferences. Capsules can be administered directly into the horse's mouth, hidden in treats, or opened and the contents mixed with feed. Tablets may be crushed and mixed with a palatable vehicle such as applesauce, molasses, or a small amount of sweet feed. Oral solutions offer the most flexibility for dose adjustments and can be administered via oral syringe. For horses that are difficult to medicate, mixing gabapentin with a small amount of highly palatable feed and ensuring complete consumption is often the most reliable approach. The medication can be given with or without food, though administration with a small meal may improve palatability and compliance.

If a dose of gabapentin is missed, the general recommendation is to give the missed dose as soon as it is remembered, unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Doubling up on doses to compensate for a missed dose is not recommended, as this could increase the risk of side effects. For horses on twice or three times daily dosing, maintaining consistent intervals between doses helps optimize therapeutic blood levels. Owners should contact their veterinarian if multiple doses are missed or if they are uncertain about how to proceed after a missed dose.

Completion of the prescribed treatment course is important for achieving optimal therapeutic outcomes with gabapentin. For chronic conditions, ongoing treatment may be necessary to maintain clinical improvement. If discontinuation is planned after extended use, gradual tapering is generally recommended rather than abrupt cessation, as this approach helps prevent potential rebound anxiety or other withdrawal-related effects. The tapering schedule should be determined by the veterinarian based on the duration of treatment and the dose being used. Owners should not stop gabapentin therapy without consulting their veterinarian, even if the horse appears to be doing well, as premature discontinuation may result in return of clinical signs.

Gabapentin is generally well-tolerated in horses when administered at appropriate doses under veterinary supervision. The medication's safety profile is one of its advantages compared to some traditional sedatives and anxiolytics. Most horses receiving gabapentin experience minimal adverse effects, particularly when dosing is initiated conservatively and increased gradually as needed. However, as with any medication, owners should be aware of potential side effects and monitor their horses during treatment. Individual variation in drug response means that some horses may be more sensitive to gabapentin's effects than others.

The most commonly observed side effects of gabapentin in horses involve mild sedation and changes in coordination. Some horses may appear slightly drowsy or less reactive than usual, particularly when first starting the medication or after dose increases. Mild ataxia, characterized by subtle gait abnormalities or reduced coordination, has been reported in some horses, especially at higher doses. These effects are typically transient and often diminish as the horse adjusts to the medication over several days to a week. Gastrointestinal effects such as mild changes in appetite, loose stool, or altered manure consistency are occasionally observed but are generally self-limiting and resolve without intervention.

Moderate side effects requiring attention include more pronounced sedation that interferes with normal activities, persistent ataxia that creates safety concerns, or behavioral changes such as unusual agitation or depression. Some horses may exhibit paradoxical reactions where anxiety appears to worsen rather than improve, though this is uncommon. Changes in urination patterns have been reported occasionally, as gabapentin is primarily eliminated through the kidneys. If moderate side effects persist beyond the initial adjustment period or worsen over time, veterinary consultation is warranted to determine whether dose adjustment or medication discontinuation is appropriate.

Serious side effects from gabapentin are rare in horses but require immediate veterinary attention if observed. Severe ataxia that prevents normal standing or movement, signs of allergic reaction such as hives, facial swelling, or difficulty breathing, and marked depression or unresponsiveness warrant urgent veterinary evaluation. Horses with pre-existing kidney disease may be at increased risk for gabapentin accumulation and toxicity, as the drug is primarily excreted unchanged through the kidneys. Any sudden onset of colic symptoms, severe lethargy, or collapse during gabapentin therapy should be treated as an emergency, though direct causation by gabapentin would be unusual.

Long-term use considerations with gabapentin include the potential for tolerance development, where the same dose becomes less effective over time, necessitating dose adjustments. Some horses may experience weight changes during extended gabapentin therapy, warranting attention to body condition and dietary management. Periodic veterinary reassessment during long-term treatment helps identify any emerging issues and ensures the treatment plan remains appropriate. Abrupt discontinuation after prolonged use should be avoided, as gradual tapering is recommended to prevent potential rebound effects. Owners should promptly report any new or worsening symptoms to their veterinarian, as early intervention often allows for successful management of side effects while maintaining therapeutic benefits.

Gabapentin should not be administered to horses with known hypersensitivity or allergic reactions to gabapentin or any components of the formulation. Although true allergic reactions to gabapentin are uncommon, horses that have previously experienced adverse reactions to the medication should not receive it again. Cross-reactivity with pregabalin, a related gabapentinoid medication, may exist, and horses with documented sensitivity to pregabalin should be treated with caution if gabapentin use is considered. Thorough disclosure of any previous adverse drug reactions to the prescribing veterinarian helps ensure safe medication selection and allows for appropriate alternatives to be considered if needed.

Renal dysfunction represents an important consideration for gabapentin use, as the drug is primarily eliminated unchanged through the kidneys. Horses with significant kidney disease may accumulate gabapentin to potentially toxic levels, as impaired renal function reduces the body's ability to clear the medication. For horses with known or suspected renal compromise, dose reduction or extended dosing intervals may be necessary, and some cases may preclude gabapentin use entirely. Baseline kidney function assessment through blood work may be recommended before initiating gabapentin therapy in horses with risk factors for renal disease. Ongoing monitoring of kidney function during extended treatment helps identify any emerging renal issues that could affect drug handling.

Considerations for pregnant and lactating mares regarding gabapentin use in horses are not well established, as limited data exists on the medication's effects on equine reproduction and development. In human medicine, gabapentin crosses the placenta and is excreted in breast milk, raising concerns about potential fetal and neonatal exposure. Until more information becomes available, gabapentin use in pregnant mares should be approached with caution and reserved for situations where the potential benefits clearly outweigh possible risks. Breeding stallions should also be evaluated carefully, as the effects of gabapentin on equine fertility and sperm parameters have not been thoroughly studied. Lactating mares receiving gabapentin may pass the medication to nursing foals, warranting consideration of alternative approaches or close monitoring.

Other medical conditions that may affect gabapentin use include concurrent neurological disorders, as the medication's effects on the central nervous system could potentially complicate the clinical picture or interact with the underlying condition. Horses with severe debilitation or compromised overall health status require careful evaluation before initiating any medication therapy. The drug's sedative properties, while generally mild, may be problematic for horses with certain respiratory conditions or those requiring full alertness for safety reasons. Competition and performance horses face additional restrictions, as gabapentin is a prohibited substance under many regulatory bodies including FEI and USEF, with detection possible for extended periods after administration. Horses actively competing must observe appropriate withdrawal periods, and current regulations should always be verified with the relevant governing organization.

While gabapentin has a relatively favorable drug interaction profile compared to many other medications, several important interactions warrant consideration when using this medication in horses. The most significant potential interactions involve other central nervous system depressants, where additive sedative effects may occur. When gabapentin is combined with sedatives such as acepromazine, detomidine, xylazine, or other alpha-2 agonists, enhanced sedation and more pronounced ataxia may result. While such combinations may occasionally be intentionally used under veterinary direction, the potential for excessive sedation requires careful dose adjustments and monitoring. Similar caution applies when combining gabapentin with opioid medications, phenothiazine tranquilizers, or general anesthetics.

Interactions with antacid medications deserve consideration, as aluminum and magnesium-containing antacids can reduce gabapentin absorption from the gastrointestinal tract. Horses receiving omeprazole, ranitidine, or other gastric acid-reducing medications typically do not experience significant interactions, as these work through different mechanisms than traditional antacids. However, if antacid administration is necessary, separating the doses by at least two hours from gabapentin administration helps minimize potential absorption interference. This consideration is particularly relevant for horses with concurrent gastric ulcer treatment, where timing of multiple medications requires attention.

Gabapentin may potentially interact with other medications that affect renal function or are primarily eliminated through the kidneys. Since gabapentin undergoes minimal metabolism and is excreted largely unchanged in urine, any condition or medication that impairs kidney function could affect gabapentin clearance and potentially lead to accumulation. Non-steroidal anti-inflammatory drugs, which are commonly used in horses and can affect renal blood flow, warrant consideration when used concurrently with gabapentin, particularly in horses with any degree of renal compromise. Aminoglycoside antibiotics and other potentially nephrotoxic medications require similar attention. Regular monitoring of kidney function may be advisable during long-term concurrent therapy with multiple medications.

For competition horses, the interaction between gabapentin and regulatory drug testing creates important practical considerations beyond pharmacological drug interactions. Gabapentin is classified as a prohibited substance under FEI, USEF, and most racing commission rules. The detection window for gabapentin can extend for days to weeks after administration, depending on the dose used and individual horse factors. Horses receiving gabapentin therapy require appropriate withdrawal periods before competition, and current regulations should always be verified as rules evolve. The combination of gabapentin with other prohibited substances may complicate detection and withdrawal time calculations. Competition horses should have accurate medication records maintained, and consultation with a veterinarian familiar with regulatory requirements is essential for ensuring compliance while managing the horse's medical needs.

Monitoring requirements during gabapentin therapy include observation for therapeutic response and potential adverse effects. During the initial treatment period, owners should closely watch for signs of excessive sedation, ataxia, or behavioral changes that might indicate the dose requires adjustment. Keeping a written log of the horse's behavior, anxiety levels, and any changes from baseline helps track progress and facilitates meaningful discussions with the veterinarian during follow-up appointments. For horses with pre-existing kidney concerns or those on long-term therapy, periodic blood work to assess renal function may be recommended. Physical examination and reassessment of the original condition at regular intervals ensure the treatment plan remains appropriate.

Special considerations apply to specific horse populations when using gabapentin. Foals and young horses have different pharmacokinetic profiles than adults, and limited data exists on appropriate gabapentin dosing in juvenile equines. Conservative dosing and careful monitoring are advisable if gabapentin use is necessary in young horses. Geriatric horses may have age-related reductions in kidney function that affect gabapentin clearance, potentially necessitating dose adjustments or extended dosing intervals. Horses with chronic conditions such as pituitary pars intermedia dysfunction (PPID), equine metabolic syndrome (EMS), or other systemic diseases require comprehensive evaluation of how gabapentin therapy fits within their overall management plan.

Competition and performance horse considerations represent a critical area of concern for gabapentin use. The medication is classified as a prohibited substance under FEI (Fédération Équestre Internationale), USEF (United States Equestrian Federation), and most state racing commission rules. Detection times may exceed withdrawal recommendations, creating risk for positive tests even when medication is stopped before competition. The specific detection period varies based on dose, duration of treatment, and individual horse factors. Owners and trainers of competition horses must verify current regulations with the relevant governing body, as rules are subject to change. Maintaining accurate medication records is essential, and gabapentin administration should be factored into competition schedules well in advance. When in doubt about clearance times, competing should be avoided.

Administration precautions include safe handling of the medication and ensuring accurate dosing. Gabapentin capsules and tablets should be stored securely away from children and other animals. Human exposure to veterinary doses is not expected to cause significant harm, but accidental ingestion should prompt consultation with a poison control center. Proper measurement of oral solution formulations ensures accurate dosing. The medication should not be administered to horses other than those for whom it was prescribed. Proper disposal of unused medication should follow local guidelines for pharmaceutical waste, typically returning unused medication to a pharmacy or utilizing designated drug take-back programs.

Long-term use of gabapentin requires periodic reassessment of the treatment plan. Tolerance development may necessitate dose increases over time to maintain therapeutic effect, though this does not occur in all horses. The underlying condition should be reevaluated periodically to determine whether continued gabapentin therapy remains necessary or whether alternative approaches might be considered. Abrupt discontinuation after extended use is not recommended, as gradual tapering helps prevent potential rebound anxiety or other withdrawal effects. The tapering schedule should be determined by the veterinarian based on the duration and dose of treatment. Any significant changes in the horse's health status, environment, or management that might affect the original condition should prompt discussion with the veterinarian about potential treatment plan modifications.

Proper storage of gabapentin is essential for maintaining medication efficacy and safety. Gabapentin capsules, tablets, and oral solutions should be stored at controlled room temperature, typically between 68°F and 77°F (20°C to 25°C). Brief excursions to temperatures between 59°F and 86°F (15°C to 30°C) are generally acceptable, but prolonged exposure to extreme temperatures should be avoided. In barn environments, this means storing gabapentin in a temperature-controlled area rather than in tack rooms that may experience significant temperature fluctuations. Medication should be protected from excessive moisture, so storage in damp areas or bathroom-style medicine cabinets is not recommended. The original container provides appropriate protection when kept sealed between uses.

Safe handling practices for gabapentin include keeping the medication in its original labeled container to prevent confusion with other medications. Human exposure to gabapentin through normal handling poses minimal risk, but basic precautions such as washing hands after handling medication are advisable. If gabapentin oral solution is used, avoiding contact with eyes and washing hands after measuring doses is recommended. Accidental ingestion of gabapentin by humans, while not typically dangerous at veterinary doses, should prompt consultation with a poison control center or healthcare provider. Children and unauthorized persons should not have access to stored medications, and gabapentin should be kept in a secure location away from curious horses who might access medication storage areas.

Expiration dates should be observed for all gabapentin products, as the manufacturer's dating ensures potency and stability. Using expired gabapentin may result in reduced therapeutic effect or unpredictable drug behavior. Oral solutions may have shorter shelf lives than solid dosage forms, particularly after opening, so attention to beyond-use dating for opened containers is important. Signs of medication degradation may include changes in color, consistency, or odor of liquid formulations, or visible deterioration of tablets or capsules. Any medication showing signs of degradation should not be used and should be properly disposed of. Proper disposal of unused or expired gabapentin involves following local guidelines for pharmaceutical waste, which typically include returning medications to a pharmacy for disposal or utilizing community drug take-back programs. Gabapentin should not be disposed of by flushing down toilets or throwing in regular trash where it could be accessed by animals or contaminate water supplies.

Draft horses receiving gabapentin therapy require attention to appropriate dosing for their substantial body mass. Breeds such as Clydesdales, Percherons, Belgians, and Shires commonly weigh between 1,600 and 2,200 pounds or more, necessitating larger absolute doses to achieve therapeutic drug levels. However, draft breeds may have different metabolic characteristics than lighter horses, and individual response to gabapentin should be carefully monitored. The gentle temperament common to many draft breeds may make anxiety less frequently encountered than in hotter-blooded types, though draft horses are certainly not immune to behavioral issues. When gabapentin is indicated for draft horses, accurate weight determination through scale measurement is particularly valuable given the large quantities of medication involved and the cost implications of treatment.

Light horse breeds and warmbloods represent the most common population receiving gabapentin therapy in equine practice. Standard dosing protocols generally apply to these breeds, with individual adjustments based on response. Performance horses in these categories frequently encounter gabapentin consideration for competition-related anxiety or headshaking syndrome, though regulatory restrictions significantly limit use in actively competing horses. Warmbloods and sport horses with anxiety related to competition stress, trailering, or specific phobias may benefit from gabapentin as part of a comprehensive behavioral management approach. Thoroughbreds and other hot-blooded breeds may exhibit heightened anxiety responses that make them good candidates for anxiolytic therapy, though their athletic careers often conflict with medication restrictions.

Ponies and miniature horses require careful attention to weight-based dosing, as these small equines are frequently overdosed when medications are estimated rather than precisely calculated. A miniature horse weighing 200 pounds requires dramatically different dosing than a standard horse weighing 1,000 pounds. The oral solution formulation of gabapentin offers advantages for precise dosing in small equines, as capsule and tablet strengths may not divide appropriately for lighter weights. Metabolic differences in ponies, including their tendency toward easier weight gain and metabolic disorders, may affect drug handling, though specific pharmacokinetic data in pony breeds is limited. Close monitoring during gabapentin therapy helps ensure appropriate dosing and early detection of any adverse effects.

Breed-specific genetic conditions may influence gabapentin use in certain populations. Quarter Horses and related breeds carrying HYPP (Hyperkalemic Periodic Paralysis) do not have specific gabapentin contraindications, but the complex medical management these horses require warrants comprehensive veterinary planning for any medication additions. Arabian horses with conditions such as Cerebellar Abiotrophy may have neurological presentations that require careful differentiation from potential gabapentin side effects. Appaloosas with Congenital Stationary Night Blindness may already exhibit anxiety related to visual impairment, and gabapentin consideration in these horses requires understanding the underlying condition. Friesians with megaesophagus require attention to oral medication administration, as swallowing difficulties could affect gabapentin delivery. For any horse with breed-specific genetic conditions, consultation with a veterinarian familiar with both the condition and gabapentin use ensures appropriate treatment planning.

Within the gabapentinoid class, pregabalin (Lyrica) represents the most closely related medication to gabapentin. Pregabalin shares gabapentin's mechanism of action, binding to voltage-gated calcium channel alpha-2-delta subunits, but exhibits higher potency and more predictable absorption characteristics. In equine medicine, pregabalin has been investigated for similar indications as gabapentin, including headshaking syndrome and neuropathic pain. The choice between gabapentin and pregabalin typically involves considerations of cost, dosing convenience, and individual patient response. Pregabalin may offer advantages in some cases, but its higher cost per dose and controlled substance status in some jurisdictions affect its practical use. Horses that do not respond adequately to gabapentin may be candidates for pregabalin trial under veterinary direction.

Alternative anxiolytic medications available for horses include traditional sedatives and specific anti-anxiety agents. Trazodone has gained popularity as an equine anxiolytic, working through serotonin receptor modulation to produce calming effects. Acepromazine remains widely used for anxiety and sedation, though its longer duration and more pronounced sedative effects differ from gabapentin's profile. Alpha-2 agonists such as detomidine and xylazine provide reliable sedation but are typically reserved for procedural use rather than ongoing anxiety management. Reserpine has historical use for behavioral modification in horses but carries significant concerns about side effects and withdrawal times. The selection among these alternatives depends on the specific clinical situation, duration of treatment needed, competition status, and individual horse factors.

Complementary therapies and non-pharmaceutical approaches often work alongside gabapentin or serve as alternatives depending on the situation. Environmental management addressing sources of anxiety, consistent training approaches, and stress reduction strategies form the foundation of behavioral management. Nutritional supplements including magnesium, thiamine, and various calming formulations are frequently used by horse owners, though evidence for efficacy varies. Physical therapies such as massage, acupuncture, and chiropractic care may benefit horses with anxiety related to physical discomfort. For headshaking syndrome specifically, management strategies including nose nets, UV-protective masks, and environmental modifications may reduce symptoms alongside or instead of medication. Veterinary behaviorists can provide valuable guidance for complex anxiety cases, helping develop comprehensive treatment plans that may include multiple modalities. Any substitution of medications or addition of complementary therapies should involve veterinary consultation to ensure safety and appropriate integration with existing treatment plans.